Chemmino dedicates to developing and utilizing a range of novel illuminating materials to design, develop, and manufacture a series of miniature yet affordable diagnostic devices for point-of-care and even consumer level biomedical analyses.

GoldPorp Pharma dedicates to the discovery and clinical development of novel drugs for the treatment of advanced cancer. We envision a world where advanced cancer is just a treatable chronic disease. We have developed proprietary anticancer compounds that provide much better efficacy than commonly used platinum-based cancer drugs for treatment of advanced metastasized cancer and potentially replace existing chemotherapy.

L'Ord'invent Limited aims at inventing, devising, and refining rapid tools for diagnosing early cancer and prediction of cancer onset, treatment response and relapse. Also aims to transform rapid tools from hospital/laboratory tests to point-of-care and home self-monitoring tests.

ChemTechChem is dedicated to developing technologies and multi-omics platforms, which support basic and translational research in drug discovery. The platforms generate integrated big data to build robust and rigorous repositories (e.g. Omics Suite, Omics Atlas, Biobank) – translating omics insights into predictable outcomes - for the discovery of new targeted chemotherapy against advanced and metastatic cancers.

AILSI is a biotechnology company powered by generative artificial intelligence. AILSI has developed a comprehensive AI system that integrates disease biology with medicinal chemistry. By utilizing advanced deep learning techniques, along with internally developed computational biology tools and molecular modeling methods, they focus on discovering new targets and designing innovative drug candidates to address unmet clinical needs.

Hong Kong Earth-Abundant Metal Materials and Catalysis Company Limited is a high-tech enterprise driven by independent innovation. We specialize in the R&D and industrial application of high-efficiency, low-cost earth-abundant metal catalysts, delivering groundbreaking catalytic technologies for the cutting-edge product development in chemical synthesis, biopharmaceuticals, and new energy materials. Our technologies empower clients to accelerate product innovation and R&D processes while effectively reducing production energy consumption and costs.

DiagnoVEX Therapeutics Limited is pioneering the future of cancer care by developing innovative, first-in-class monoclonal antibodies that target the fundamental drivers of cancer. Our mission is to translate cutting-edge research into practical, clinically applicable solutions, including diagnostic kits and targeted therapies, that enable personalized treatment approaches. DiagnoVEX aims to improve patient outcomes, broaden therapeutic options, and revolutionize the landscape of cancer diagnosis and treatment.

Hong Kong Eclevia Chemicals Limited is a specialty chemical company dedicated to the development and supply of ultra-high-purity organic chemicals. Its products serve advanced industries including semiconductors, displays, and pharmaceuticals, covering molecular building blocks, key intermediates, and high-purity solvents. Eclevia focuses on precision synthesis, strict quality control, and reliable global supply.

MetAb, is dedicated to improving the outcomes of ovarian cancer patients by translating our molecular research findings into clinical applications. Established in 2024 and backed by 20 years of experience in ovarian cancer research, our mission is to develop therapeutic antibodies that offer improved clinical benefits, reduced drug resistance, and affordable costs.

Our product, Blocking Antibody, is designed to target a tumour-associated antigen, which has a significant association with poor prognosis in different cancer types. This innovation can lead to a first-in-class therapeutic antibody in combating chemo-resistant and metastatic ovarian cancer.

Under the lead of our founder, Prof. WONG, we hope our therapeutic antibody can empower women affected by ovarian cancer and help transform this daunting diagnosis into a story of hope and resilience.

STEM Synergy Biosciences emerges from years of dedicated research into the critical hallmark of ‘stemness’ in cancer cells, a feature well-known for its
contribution to therapy resistance and tumor recurrence. Our focus is to address cancer at its roots by specifically targeting stemness in hepatocellular carcinoma (HCC), one of the most challenging solid tumors to treat. We are pioneering innovative strategies to enhance treatment efficacy and improving patient outcomes. We are also developing advanced prognostic methods to better predict drug responses and anticipate tumor recurrence. Through our cutting-edge approach, we strive to transform cancer treatment and offer renewed hope to patients confronting this complex disease.